Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesZLSCF EV-to-OCF is -2.94 as of Aug. 07, 2026. The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, ZYUS Life Sciences ranks better than 75.57% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ZYUS Life Sciences's Enterprise Value is $16.62 Mil.
ZYUS Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.66 Mil. Therefore, ZYUS Life Sciences's EV-to-OCF for today is -2.94.
The historical rank and industry rank for ZYUS Life Sciences's EV-to-OCF or its related term are showing as below:
ZLSCF'
s EV-to-OCF Range Over the Past 10 Years
Min: -18.94 Med: -6.46 Max: -2.94
Current: -2.94
During the past 5 years, the highest EV-to-OCF of ZYUS Life Sciences was -2.94. The lowest was -18.94. And the median was -6.46.
ZLSCF's EV-to-OCF is ranked better than 75.57% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.87
vs ZLSCF: -2.94
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ZYUS Life Sciences (OTCPK:ZLSCF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ZYUS Life Sciences's PE Ratio (TTM) for today is calculated as:
ZYUS Life Sciences's share price for today is $0.0137.
ZYUS Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.196.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ZYUS Life Sciences EV-to-OCF Related Terms
ZYUS Life Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ZYUS Life Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's EV-to-OCF falls into.
ZYUS Life Sciences's current Enterprise Value is $16.62 Mil.
ZYUS Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (ZLSCF) has a EV-to-OCF of -2.94 as of Aug. 07, 2026. According to the industry distribution chart, ZYUS Life Sciences ranks #246 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is ZYUS Life Sciences' EV-to-OCF too high?
ZYUS Life Sciences' current EV-to-OCF is -2.94. Based on the distribution chart, ZYUS Life Sciences ranks #246 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does ZYUS Life Sciences' EV-to-OCF compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #246 out of 1007 companies for EV-to-OCF. This places ZYUS Life Sciences in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.87, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current EV-to-OCF is -2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.01 — trading 97.7% below its estimated fair value. The current EV-to-OCF is -2.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current EV-to-OCF is -2.94 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLSCF has been successfully added to your 
